Early response to therapy and survival in multiple myeloma

British Journal of Haematology

Volumn 125, Issue 2, 2004, Pages 162-166

  Schaar, C G ^a,e   Kluin Nelemans, J C ^b   Le Cessie, S ^a   Franck, P F H ^c   Te Marvelde, M C ^d   Wijermans, P W ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

^d Integraal Kankercentrum West   (Netherlands)

^e Gelre Ziekenhuizen ^*  (Netherlands)

Author keywords

Monoclonal protein; Multiple myeloma; Prognostic factors; Response; Survival

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; M PROTEIN; MELPHALAN; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CREATININE BLOOD LEVEL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2042511646     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04884.x     Document Type: Article

References (18)

1. Armitage, J.O., Weisenburger, D.D., Hutchins, M.M., Moravec, D.F., Dowling, M., Sorensen, S., Mailliard, J., Okerbloom, J., Johnson, P.S., Howe, D., Bascom, G.K., Casey, J., Linder, J. & Purtilo, D.T. (1986) Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. Journal of Clinical Oncology, 4, 160-164.
2. Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P., White, D. & Willan, A. (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. British Journal of Cancer, 57, 94-99.
3. Blade, J., Lopez-Guillermo, A., Bosch, F., Cervantes, F., Reverter, J.C., Montserrat, E. & Rozman, C. (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematolology, 88, 117-121.
4. Boccadoro, M., Marmont, F., Tribalto, M., Fossati, G., Redoglia, V., Battaglio, S., Massaia, M., Gallamini, A., Comotti, B. & Barbui, T. (1989) Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. Journal of Clinical Oncology, 7, 119-125.
5. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
6. Durie, B.G., Salmon, S.E. & Moon, T.E. (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood, 55, 364-372.
7. Durie, B.G., Stock-Novack, D., Salmon, S.E., Finley, P., Beckord, J., Crowley, J. & Coltman, C.A. (1990) Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood, 75, 823-830.
8. Gaynon, P.S., Desai, A.A., Bostrom, B.C., Hutchinson, R.J., Lange, B.J., Nachman, J.B., Reaman, G.H., Sather, H.N., Steinherz, P.G., Trigg, M.E., Tubergen, D.G. & Uckun, F.M. (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer, 80, 1717-1726.
9. Hansen, O.P., Jessen, B. & Videbaek, A. (1973) Prognosis of myelomatosis on treatment with prednisone and cytostatics. Scandinavian Journal of Haematology, 10, 282-290.
10. Hobbs, J.R. (1969) Growth rates and responses to treatment in human myelomatosis. British Journal of Haematology, 16, 607-617.
11. Kaiser, U., Oldenburg, M., Jaques, G., Auerbach, B. & Havemann, K. (1996) Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma. Annals of Hematology, 73, 121-126.
12. Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 64-70.
13. McLaughlin, P. & Alexanian, R. (1982) Myeloma protein kinetics following chemotherapy. Blood, 60, 851-855.
14. Marmont, F., Levis, A., Falda, M. & Resegotti, L. (1991) Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. Annals of Oncology, 2, 191-195.
15. Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Saso, R., Horton, C. & Mehta, J. (2000) Early response to infusional chemotherapy is an independent prognostic factor in newly-diagnosed IgG and IgA multiple myeloma (abstract no 3277). Blood, 96, 758a.
16. Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S. & Mehta, J. (2002) Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplantation, 30, 673-679.
17. Sullivan, P.W. & Salmon, S.E. (1972) Kinetics of tumor growth and regression in IgG multiple myeloma. Journal of Clinical Invesigation, 51, 1697-1708.
18. Waldmann, T.A. & Strober, W. (1969) Disorders of immunoglobulin metabolism. New England Journal of Medicine, 281, 1170-1177.